Campbell Newman Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-10,614
| Closed | -$494K | – | 125 |
|
|
2020
Q4 | $494K | Buy |
10,614
+793
| +8% | +$36.9K | 0.06% | 108 |
|
|
2020
Q3 | $417K | Buy |
9,821
+177
| +2% | +$7.52K | 0.05% | 109 |
|
|
2020
Q2 | $463K | Buy |
9,644
+95
| +1% | +$4.56K | 0.06% | 101 |
|
|
2020
Q1 | $439K | Sell |
9,549
-458
| -5% | -$21.1K | 0.08% | 94 |
|
|
2019
Q4 | $601K | Sell |
10,007
-20
| -0.2% | -$1.2K | 0.08% | 97 |
|
|
2019
Q3 | $567K | Sell |
10,027
-81
| -0.8% | -$4.58K | 0.08% | 100 |
|
|
2019
Q2 | $563K | Buy |
10,108
+671
| +7% | +$37.4K | 0.08% | 102 |
|
|
2019
Q1 | $476K | Buy |
9,437
+234
| +3% | +$11.8K | 0.07% | 108 |
|
|
2018
Q4 | $371K | Buy |
9,203
+965
| +12% | +$38.9K | 0.06% | 109 |
|
|
2018
Q3 | $571K | Buy |
8,238
+430
| +6% | +$29.8K | 0.08% | 97 |
|
|
2018
Q2 | $591K | Buy |
7,808
+3,854
| +97% | +$292K | 0.09% | 92 |
|
|
2018
Q1 | $208K | Buy |
3,954
+202
| +5% | +$10.6K | 0.03% | 127 |
|
|
2017
Q4 | $200K | Buy |
+3,752
| New | +$200K | 0.03% | 128 |
|
|
2017
Q3 | – | Sell |
-2,693
| Closed | -$212K | – | 131 |
|
|
2017
Q2 | $212K | Buy |
2,693
+126
| +5% | +$9.92K | 0.04% | 123 |
|
|
2017
Q1 | $213K | Buy |
+2,567
| New | +$213K | 0.04% | 116 |
|